ABSTRACT
Objective:To investigate the efficacy of compound Lactobacillus acidophilus tablets combined with bismuth-containing quadruple therapy in the treatment of Helicobacter pylori-positive (Hp +) chronic non-atrophic gastritis and its effect on Lactobacillus and Escherichia coli.Methods:A total of 104 patients with Hp + chronic non-atrophic gastritis who received treatment in Affiliated Hospital of Shaoxing University from March 2019 to September 2020 were included in this study. They were randomly divided into control and observation groups, with 52 patients in each group. The control group was treated with bismuth-containing quadruple therapy. The observation group was treated with compound Lactobacillus acidophilus tablets (2 tablets once, three times per day) based on bismuth-containing quadruple therapy. Two groups were treated for 2 successive weeks. The endoscopic grading score of gastric mucosa, improvement in pathological grading of gastric mucosa, Hp eradication rate, and Lactobacillus and Escherichia coli levels were compared between the two groups. Results:After treatment, endoscopic grading score of gastric mucosa (gastric mucosa inflammation, inflammation activity, atrophy, and intestinal metaplasia) in the observation group was (1.31 ± 0.18) points, (1.24 ± 0.18) points, (1.15 ± 0.16) points, (1.04 ± 0.15) points, respectively, which was superior to (1.73 ± 0.25) points, (1.59 ± 0.21) points, (1.44 ± 0.19) points, (1.30 ± 0.18) points in the control group ( t = 3.67, 3.80, 4.17, 4.52, all P < 0.01). Improvement in pathological grading of gastric mucosa in the observation group was significantly higher than that in the control group [94.23% (49/52) vs. 78.85% (41/52), χ2 = 4.04, P < 0.05]. Hp eradication rate in the observation group was significantly higher than that in the control group [92.31% (48/52) vs. 75.00% (39/52), χ2 = 4.50, P < 0.05]. After treatment, the amount of Lactobacillus and Escherichia coli in the observation group were (8.30 ± 0.95) copies and (8.04 ± 0.95) copies, which were significantly greater than (7.51 ± 0.93) copies and (8.30 ± 0.95) copies in the control group ( t = 4.02, 3.75, both P < 0.01). Conclusion:Compound Lactobacillus acidophilus tablets combined with bismuth-containing quadruple therapy is highly effective on Hp + chronic non-atrophic gastritis and it can effectively improve intestinal microflora.
ABSTRACT
Objective To investigate the effect of compound Lactobacillus acidophilus on the levels of serum SP , VIP, 5-HT, IL-6 and TNF-αin patients with diarrhea-predominant irritable bowel syndrome ( IBS) .Methods 82 cases of patients with diarrhea -predominant irritable bowel syndrome ( IBS) from November 2015 to November 2016 in our hospital were selected,and randomly divided into two groups.30 patients in observation group were treated with compound Lactobacillus acidophilus tablets and 52 patients in control group were treated with trimebutine maleate capsule.The levels of serum SP, VIP, 5-HT, IL-6 and TNF-α,quality of life score,clinical curative effect and adverse reaction were observed and compared before and after treatment.Results After treatment,the diarrhea, abdominal distention, defecation frequency and abnormal rate of stool were significantly lower than those before treatment(P <0.05), the levels of SP,VIP,5-HT,IL-6 and TNF-αin serum were significantly lower than those before treatment(P <0.05),and the treatment group were lower than those of the control group.After treatment, the mental status, emotional control and work status scores of the observation group were higher than those of the control group,and the effective rate of the observation group 86.7%was significantly higher than the control group 61.5%,the differences between the two groups were statistically significant (P <0.05).There was no significant adverse events were observed during the treatment.Conclusion Compound Lactobacillus acidophilus is effective in the treatment of diarrhea-predominant irritable bowel syndrome.It can restore the levels of serum SP, VIP, 5-HT, IL-6 and TNF-αin patients with diarrhea-predominant irritable bowel syndrome and improve the quality of life .